Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Could Swedish 'yellow cards' be substituted by E-coded summaries?

C Jorup-Rönström1, M Keisu, B E Wiholm

  • 1Department of Infectious Diseases, Danderyd Hospital, Sweden.

Drug Safety
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2012
Same author

Drug-induced liver injury in humans: the case of ximelagatran.

Handbook of experimental pharmacology·2009
Same author

Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.

International journal of clinical pharmacology and therapeutics·2008
Same author

An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.

Clinical pharmacology and therapeutics·2007
Same author

Drug-attributed anaphylaxis.

Pharmacoepidemiology and drug safety·2004
Same author

Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.

Current medical research and opinion·2002

Reporting adverse drug reactions (ADRs) is crucial for patient safety. This study found that only 21% of ADRs identified in patient records were reported, highlighting a significant under-reporting issue in pharmacovigilance.

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Clinical Epidemiology
  • Infectious Diseases

Background:

  • The 'yellow card' system is the primary method for reporting adverse drug reactions (ADRs) in Sweden.
  • Effective ADR reporting is essential for monitoring drug safety post-marketing.

Purpose of the Study:

  • To evaluate the completeness of ADR reporting from a hospital department.
  • To assess the potential of integrating ICD codes into ADR surveillance.

Main Methods:

  • Retrospective review of 2490 patient case summaries from 1986.
  • Identification of ADRs using International Classification of Disease (ICD) codes.
  • Comparison of identified ADRs with reports submitted to the Swedish Adverse Drug Reactions Advisory Committee.

Related Experiment Videos

Main Results:

  • Of 48 identified ADR cases, only 10 (21%) were reported via the 'yellow card' system.
  • Three additional reports were received without corresponding ADR codes in case summaries.
  • Case summary data was largely sufficient for preliminary ADR evaluation.

Conclusions:

  • Significant under-reporting of ADRs exists within the current 'yellow card' system.
  • Supplementing the 'yellow card' system with automatic referral of ICD-coded ADRs warrants further investigation.
  • A large-scale field study is recommended to explore this supplementary reporting system.